NCT05310370

HRD and Resistance to PAPPi in EOC Patients

Correlation Between Homologous Recombination Deficiency Status and Resistance to PARP Inhibitors in Chinese Epithelial Ovarian Cancer Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: Lei Li · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667 and NCT04651920). This study is to investigate the correlation between HRD and the resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in a Chinese cohort confirmed of epithelial ovarian cancer. The mutated genes, HRD score model and their relationship with the prognosis is the primary endpoint in this study. All enrolled patients will accept PARPi as maintenance therapy after the complete or partial remission of targeted lesions. A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.

Conditions

• Epithelial Ovarian Cancer
• Homologous Recombination Deficiency
• Homologous Recombination Repair Gene Mutation
• Poly(ADP-ribose) Polymerase Inhibitor
• Drug Resistance
• Progression-free Survival
• Overall Survival

Interventions

Type	Name	Description
GENETIC	Testing of homologous recombination deficiency	A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.

Timeline

• Start date: 2022-03-26
• Primary completion: 2024-03-26
• Completion: 2025-03-26
• First posted: 2022-04-04
• Last updated: 2022-04-04

Locations

1 site across 1 country: China